RenovoRx (RNXT) CMO buys 22,000 shares at $0.80 in Form 4

Q: What insider transactions were reported for RNXT in this Form 4?

The Form 4 reports that Director and Chief Medical Officer Ramtin Agah purchased 10,000 shares of RenovoRx (RNXT) common stock on 11/21/2025 and 12,000 shares on 11/24/2025.

Q: What is the role of the reporting person at RenovoRx (RNXT)?

The reporting person is identified as both a Director and an Officer, serving as the company’s Chief Medical Officer.

Q: Were the RNXT insider transactions open market purchases or another type?

The explanation of responses states that the transactions reflect open market purchases of RenovoRx’s securities.

Q: Is this RNXT Form 4 filed for one or multiple reporting persons?

The form indicates that it is filed by one reporting person, specifically the Director and Chief Medical Officer.

RenovoRx, Inc. insider trading report: Director and Chief Medical Officer Ramtin Agah reported open market purchases of RenovoRx common stock.

Filing Impact

(Moderate)

Filing Sentiment

(Positive)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

RenovoRx, Inc. insider trading report: Director and Chief Medical Officer Ramtin Agah reported open market purchases of RenovoRx common stock. On 11/21/2025, he bought 10,000 shares at a price of $0.80 per share, and on 11/24/2025 he purchased an additional 12,000 shares at $0.80 per share. After these transactions, he beneficially owned 756,460 shares of RenovoRx common stock, held directly. The filing notes that these transactions reflect open market purchases of the company’s securities.

Insider Trade Summary

Net Buyer: 22,000 shares

Net Buy 2 txns

Insider Agah Ramtin

Role Chief Medical Officer

Bought 22,000 shs ($18K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	12,000	$0.80	$10K
Purchase	Common Stock	10,000	$0.80	$8K

Holdings After Transaction: Common Stock — 756,460 shares (Direct)

Footnotes (1)

F1. Reflects open market purchases of the Issuer's securities.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions were reported for RNXT in this Form 4?

The Form 4 reports that Director and Chief Medical Officer Ramtin Agah purchased 10,000 shares of RenovoRx (RNXT) common stock on 11/21/2025 and 12,000 shares on 11/24/2025.

At what price did the RNXT insider buy shares?

Both transactions disclosed in the Form 4 show open market purchases at a price of $0.80 per share for RenovoRx common stock.

How many RNXT shares does the reporting person own after these trades?

Following the reported transactions, the filing states that 756,460 shares of RenovoRx common stock are beneficially owned by the reporting person in direct ownership.

What is the role of the reporting person at RenovoRx (RNXT)?

The reporting person is identified as both a Director and an Officer, serving as the company’s Chief Medical Officer.

Were the RNXT insider transactions open market purchases or another type?

The explanation of responses states that the transactions reflect open market purchases of RenovoRx’s securities.

Is this RNXT Form 4 filed for one or multiple reporting persons?

The form indicates that it is filed by one reporting person, specifically the Director and Chief Medical Officer.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 11/24/2025 - 06:00 PM EST

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Agah Ramtin

(Last)

(First)

(Middle)

C/O RENOVORX, INC.

2570 W EL CAMINO REAL, SUITE 320

(Street)

MOUNTAIN VIEW

94040

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
RenovoRx, Inc. [ RNXT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
11/21/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	11/21/2025		P		10,000⁽¹⁾	A	$0.8	744,460	D
Common Stock	11/24/2025		P		12,000⁽¹⁾	A	$0.8	756,460	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Reflects open market purchases of the Issuer's securities.

	/s/ Ramtin Agah	11/24/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR